Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cybin Inc (HELP)

Cybin Inc (HELP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule PR Newswire - Tue Jul 21, 9:54AM CDT

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program

HELP : 7.60 (-1.30%)
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates FinancialNewsMedia - Tue Jul 21, 7:30AM CDT

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

HELP : 7.60 (-1.30%)
CMPS : 10.85 (-3.73%)
ATAI : 7.18 (+0.14%)
JNJ : 266.73 (+0.29%)
LLY : 1,220.66 (+1.93%)
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule FinancialNewsMedia - Tue Jul 21, 7:15AM CDT

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program  Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data...

HELP : 7.60 (-1.30%)
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule GlobeNewswire - Tue Jul 21, 6:50AM CDT

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability...

HELP : 7.60 (-1.30%)
HELP.NE : 10.8000 (-1.19%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity FinancialNewsMedia - Tue Jun 30, 8:00AM CDT

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

HELP : 7.60 (-1.30%)
CMPS : 10.85 (-3.73%)
GHRS : 27.96 (+0.76%)
JNJ : 266.73 (+0.29%)
DFTX : 41.96 (-1.62%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity GlobeNewswire - Tue Jun 30, 8:00AM CDT

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients...

HELP : 7.60 (-1.30%)
CMPS : 10.85 (-3.73%)
GHRS : 27.96 (+0.76%)
JNJ : 266.73 (+0.29%)
DFTX : 41.96 (-1.62%)
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results GlobeNewswire - Mon Jun 29, 6:40AM CDT

- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE,...

HELP : 7.60 (-1.30%)
HELP.NE : 10.8000 (-1.19%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End Barchart - Sun Jun 28, 4:00PM CDT

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 7.60 (-1.30%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End Barchart - Sat Jun 27, 4:00PM CDT

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 7.60 (-1.30%)
Cybin's Phase Three Depression Data Could Rewrite Investor Expectations by Year End Barchart - Fri Jun 26, 4:01PM CDT

Barchart Research What to Expect from HELP Earnings HELP Generated June 26, 2026 Current Price $6.50 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 3.94% Cybin's Phase Three Depression Data...

HELP : 7.60 (-1.30%)

Barchart Exclusives

This High-Yield Bank Stock Just Raised Its Dividend by 11.7%. Barchart - Tue Jul 28, 6:30PM CDT
Citigroup announced an 11.7% increase in its quarterly dividend to $0.67 per share from $0.60 following its strongest quarterly revenue in about a decade. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.